Dec 10, 2024 8:00am EST Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
Dec 04, 2024 8:00am EST Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
Nov 26, 2024 8:00am EST Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Oct 08, 2024 8:00am EDT Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
Oct 02, 2024 8:00am EDT Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries